Sign in or register today for access to this and other blogs and discussions.
In the wake of HPS2-THRIVE, John Ryan asks William Boden, lead investigator of the AIM-HIGH trial, for his perspective on niacin and other HDL-modifying therapies. Give us your thoughts on HPS2-THRIVE.
CardioExchange is an online community hosted by the New England Journal of Medicine and Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.